Trending...
- Platinum Car Audio LLC Focuses on Customer-Driven Vehicle Audio and Electronics Solutions
- Mecpow M1: A Safe & Affordable Laser Engraver Built for Home DIY Beginners
- Postmortem Pathology Expands Independent Autopsy Services Across Colorado
Company is one of 30 selected for prestigious competition. During BIO Digital Week, attendees can watch timely, on-demand pitches and meet with ExpressCells via BIO's One-on-One Partnering.
PHILADELPHIA - PennZone -- ExpressCells, Inc. (ExpressCells), a privately-owned genetic engineering company that creates knock-in cell lines for drug discovery, will be one of the finalists presenting in the Start-Up Stadium during BIO Digital Week.
"We are honored to be selected by the judges as one of the finalists for Start-Up Stadium. We hope that all BIO Digital Week attendees view our presentation, which will be available on demand via the meeting platform."
Start-Up Stadium provides an exciting and interactive experience where key stakeholders of the early-stage life science community, investors, and strategic partners provide feedback and judge 6 minute pitches presented by start-up biotech companies. During BIO Digital Week, attendees can watch ExpressCells' pitch on-demand and meet with the company via BIO's One-on-One Partnering.
More on The PennZone
"ExpressCells is excited to be part of BIO Digital Week," Mr. Handel continued. "We hope to gain valuable feedback and to meet with both potential customers and potential investors.
About ExpressCells
ExpressCells is a private biotechnology company based in Philadelphia, PA. Its propriety genome editing technology, in combination with CRISPR/Cas9, creates advanced, knock-in cell line up to 75% faster than older processes. This technology allows ExpressCells to insert up to three genes into the same cell line.
ExpressCells' first knock-in cell lines code for bioluminescent and fluorescent proteins. These allow scientists to more see the results of their experiments in real time. ExpressCells sells both custom cell lines—each designed to meet the specific requirements of an individual scientist—and catalog cell lines. For more information, visit www.xpresscells.com.
"We are honored to be selected by the judges as one of the finalists for Start-Up Stadium. We hope that all BIO Digital Week attendees view our presentation, which will be available on demand via the meeting platform."
Start-Up Stadium provides an exciting and interactive experience where key stakeholders of the early-stage life science community, investors, and strategic partners provide feedback and judge 6 minute pitches presented by start-up biotech companies. During BIO Digital Week, attendees can watch ExpressCells' pitch on-demand and meet with the company via BIO's One-on-One Partnering.
More on The PennZone
- Summit Appoints Javier Cabeza as Data, AI, and Analytics Practice Lead
- TrueNorth Wellness Services is Excited to Participate in Give Local York
- March Is Skiing's Smartest Buying Window
- Hope Survives Launches The Hope Collective, A Curated Publication Centering Lived Experience After Brain Injury
- Cancun Airport Transportation Expands Fleet Ahead of Record Passenger Growth at Cancun International Airport
"ExpressCells is excited to be part of BIO Digital Week," Mr. Handel continued. "We hope to gain valuable feedback and to meet with both potential customers and potential investors.
About ExpressCells
ExpressCells is a private biotechnology company based in Philadelphia, PA. Its propriety genome editing technology, in combination with CRISPR/Cas9, creates advanced, knock-in cell line up to 75% faster than older processes. This technology allows ExpressCells to insert up to three genes into the same cell line.
ExpressCells' first knock-in cell lines code for bioluminescent and fluorescent proteins. These allow scientists to more see the results of their experiments in real time. ExpressCells sells both custom cell lines—each designed to meet the specific requirements of an individual scientist—and catalog cell lines. For more information, visit www.xpresscells.com.
Source: ExpressCells, Inc.
0 Comments
Latest on The PennZone
- Kilmaine Saints to Record Live Album at XL Live
- CCHR: While Damaging Antipsychotics Win Approval, Proven Non-Drug Alternatives Remain Ignored
- Arcuri Group Announces Long‑Term Partnership with WakeMed Health & Hospitals to Deliver Situational Awareness and De‑escalation Training
- KDG Announces Acquisition of Square Foot Consultants, Expanding Business and Technology Expertise
- Colonial Nissan Service Named Top 5 Auto Repair in Feasterville-Trevose for 2025
- At 25, She Became One of the Youngest AAPI Female Founders to Win One of the World's Most Prestigious Design Awards for a Lamp That Makes You Smile
- Juego Studios Extends Full-Cycle Game Development & Outsourcing Capabilities to the UAE Market
- VENUS Goes Live on CATEX Exchange As UK Financial Ltd Activates The Premier Division Of The Maya Meme's League
- Atlanta Tech Founder Seeks Clarity on Intellectual Property and Innovation Policy
- Purple Heart Recipient Honored by Hall of Fame Son In Viral Tribute Sparking National Conversation on Service Fatherhood, Healing and Legacy
- Maronda Homes Leverages Power of AI to Automate, Accelerate Home Warranty Claims Process
- ATS (The Athletic Trainer System) Releases comprehensive student health features
- Amicly Launches as a Safety-First Social App Designed to Help People Build Real, Meaningful Friendships
- Primeindexer Google indexing platform launched by SEO Danmark APS
- Kaltra Introduces New Downward-Spraying Distribution Technology to Boost Microchannel Evaporator Performance
- Talentica Announces Winners of Multi-Agent Hackathon 2026
- Special Alert: Undervalued Opportunity: IQSTEL (N A S D A Q: IQST) Positioned for Explosive Multi-Year Growth
- Triple-Digit Growth, Strategic N A S D A Q Uplist, Plus A Scalable Healthcare Rollout Model: Stock Symbol: CDIX
- Vesica Health Receives FDA Breakthrough Device Designation for AssureMDx
- Lineus Medical's SafeBreak® Vascular Added to Alliant GPO Contract